Etiology and outcome of MIS-C
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3U19AI144306-02S1
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$1,491,907Funder
National Institutes of Health (NIH)Principal Investigator
Betty DiamondResearch Location
United States of AmericaLead Research Institution
Feinstein Institute For Medical ResearchResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adolescent (13 years to 17 years)Children (1 year to 12 years)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Abstract: This proposal seeks to test two hypotheses regarding the Multisystem Inflammatory Syndrome(MIS-C) recently identified in children and young adults infected with SARS-CoV-2. Wehypothesize that there is a spectrum of disease from severe acute disease to MIS-C. SevereCov acute disease is associated with low interferon production, poor control of virus and agerminal center derived antibody response to the virus leading to long term immunity while MIS-C is associated with high interferon, efficient control of virus, but an extrafollicular derivedantibody response with poor long term immunity. We will test this hypothesis through a geneticanalysis, analysis of serum cytokines and analysis of anti-viral antibodies. We also hypothesizethat plasma metabolic profile of subjects with MIS-C will predict short term cardiac dysfunctionand long term cardiac damage.